We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · August 10, 2018

Clear Cell RCC With Multiple Small Masses

Written by
Heather R Greene MSN, FNP, AOCNP


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bradley G. Somer MD

    It appears that this patient  is likely in the favorable prognostic risk group unless there are any surprises on his labs. It is over 10 years from nephrectomy. He has resected stage 4 disease and has never seen systemic therapy. So assuming that is the case, in this category, one standard of care option would be to give targeted therapy with a VEGF inhibitor. The options in this front line healthy patient include sunitinib and pazopinib.  It would enable long term disease control, and certainly if he is symptomatic from any of the disease, this is a reasonable option. 

    It was brought up at our tumor board that in light of his disease being good risk and the patient being young and fit, high dose IL-2 is an option. The consideration is based on long term data showing a survival “tail”, albeit still quite low numbers.  It was pointed out that the toxicity is clearly more substantial, and with modern day therapy, there is no way to know at this point that there isn’t a “tail” with current options.

    However, a very reasonable option for this patient would include active surveillance which this might be the right patient for in that it is in the lungs and is progressing extremely slowly. Prospective ph 2 trial showed that subsets like these can undergo active surveillance with initiation of systemic therapy upon progression. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30196-6/abstract. This is a very reasonable approach.

    In light of his contralateral renal masses, and young age of initial presentation, we recommended seeing genetic counselor and possible germline testing.

    Consensus: No

    NCCN guideline utilized: Yes.

    Clinical Trial: No.

  • Khoury Elie

    Active surveillance Systemic therapy upon progression

  • Jan 19, 2021

    Pending Moderator approval.

Further Reading